EGFR and neoplasm: Patients from group B were newly found to have sensitizing EGFR mutations and gained access to EGFR-TKI therapy at recurrence; These patients had a PR rate of 50%, rPFS of 10 months, and rOS of 35.0 months, which appeared to be numerically inferior to group A and tumor heterogeneity may play a role.